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Background
Hypocellularity of bone marrow (BM), not associated with significant dyshematopoiesis, 
is often found in patients with isolated thrombocytopenia, but its clinical implications 
have not been studied. We prospectively studied the clinical features and natural history 
of these patients.
Methods
Adults with isolated thrombocytopenia (platelet counts ＜100×10
9/L) in the absence of 
dyshematopoiesis, cytogenetic abnormalities, or megakaryocytic hyperplasia and who 
had BM hypocellularity (below 30% in patients aged less than 60 years; below 20% in 
patients aged 60 years or more) were enrolled at Chungnam National University Hospital 
between January 2002 and December 2006. They were monitored regularly for changes 
in platelet counts or development of additional cytopenia.
Results
Twenty patients (17 men and 3 women) were enrolled in the study. The median age was 
29 years (range, 18-70 years). At initial presentation, the platelet counts ranged from 12 
×10
9/L to 99×10
9/L (median, 63×10
9/L) and were ＞50×10
9/L in 16 patients (80%). BM 
cellularity ranged from 5% to 25% (median, 15%) and was ≤10% in 6 patients (30%). 
During the median 48-month follow-up (range, 12-90 months), platelet counts of 3 of 
the 20 patients recovered to normal levels (＞150×10
9/L) after 12, 56 and 66 months. 
Three patients developed pancytopenia after 11, 70 and 90 months. Two patients were 
consistent with moderate aplastic anemia, and 1 was confirmed as having refractory cyto-
penia with multilineage dysplasia. In the remainder of the patients, platelet counts re-
mained unchanged.
Conclusion
Isolated thrombocytopenia accompanied by hypocellular marrow encompasses a group 
of heterogeneous conditions.
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INTRODUCTION
  Acquired thrombocytopenia, not accompanied by anemia 
and/or leukopenia (defined as isolated thrombocytopenia), 
is observed in amegakaryocytic thrombocytopenia [1], in-
fections including human immunodeficiency virus (HIV) in-
fection [2], nutritional deficiencies [3, 4], alcohol ingestion 
[5], and primary or secondary immune thrombocytopenia 
(ITP) [6]. A presumptive diagnosis of ITP is made when 
the history, physical examination, CBC, and examination 
of the peripheral blood smears do not suggest other causes 
for thrombocytopenia [7-9]. Bone marrow (BM) examination 
is not a prerequisite for the diagnosis of ITP in general 
but may be informative in patients older than 60 years, 
patients with systemic symptoms or abnormal signs, or pa-
tients for whom splenectomy is being considered [6, 7, 9, 
10]. Treatment is rarely indicated in ITP patients with platelet 
counts above 50×10
9/L in the absence of bleeding, trauma, 
or surgery [6, 7, 9, 10]. Thus, many patients with isolated Korean J Hematol 2011;46:128-34.
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thrombocytopenia do not undergo BM examination. 
  We observed a group of patients with isolated thrombocy-
topenia, who displayed apparent hypocellularity on BM ex-
amination that was not associated with significant dysplasia 
or megakaryocytic hyperplasia. An efficient diagnosis was 
challenging in these cases, because hypocellular marrow is 
not a recognized manifestation of ITP. If these patients had 
not undergone BM examination, they would have been con-
sidered as having ITP. A prospective study on healthy in-
dividuals with sustained platelet counts between 100×10
9/L 
and 150×10
9/L (so called borderline thrombocytopenia) re-
vealed that these individuals had 12% probability of develop-
ing autoimmune disorders within 10 years [6]. However, 
the clinical features of isolated thrombocytopenia (platelet 
counts ＜100×10
9/L) accompanied by hypocellular marrow 
and its natural history have not been studied. 
  The current diagnostic criteria and recommendations for 
hematologic disorders originate from Western Europe or 
North America, where the epidemiology of hematologic dis-
orders is quite different from that of the Oriental countries. 
For example, aplastic anemia (the most common hematologic 
disorder showing marrow hypocellularity) is not as prevalent 
in western countries as it is in the Korean population [9]. 
The present study was performed to define the clinical fea-
tures and natural history of isolated thrombocytopenia ac-
companied by marrow hypocellularity without apparent 
causes in adults. 
MATERIALS AND METHODS
1. Patient eligibility
  Adult patients aged 18 years or more with isolated throm-
bocytopenia, who had hypocellular BM (below 30% in pa-
tients aged less than 60 years; below 20% in patients aged 
60 years or more) were enrolled at Chungnam National 
University Hospital between January 2002 and December 
2006. Isolated thrombocytopenia was defined as a condition 
characterized by platelet counts below 100×10
9/L for longer 
than 3 months, with normal WBC (more than 4×10
9/L) and 
normal hemoglobin levels (12 g/dL or more in women; 13 
g / d L  o r  m o r e  i n  m e n ) .  P s e u dothrombocytopenia was ex-
cluded by thorough examination of the peripheral blood 
smear. Only patients with normal karyotype hypocellularity 
and with no significant dyshematopoiesis (less than 10% 
in each lineage) or no relative megakaryocytic hyperplasia 
(less than 5 megakaryocytes on average under a high power 
field) in the BM study were included. BM specimens were 
blindly reviewed by 2 independent pathologists. When the 
cellularities were not concordant, the mean of the 2 different 
values was accepted as the cellularity. Patients with dis-
cordant decisions on dyshematopoiesis or megakaryocyte hy-
perplasia were excluded. Patients who had viral hepatitis 
and those who were positive for anti-hepatitis A virus (HAV) 
IgM antibodies, hepatitis B surface (HBs) antigen, anti-hep-
atitis C virus (HCV) antibodies, or anti-HIV antibodies were 
excluded. Patients with autoimmune disorders were also 
excluded. Patients who were positive for anti-platelet anti-
body, platelet-associated antibody, antinuclear antibodies, 
lupus anticoagulants, or anti-cardiolipin antibodies and who 
displayed low complement (C3 or C4) levels or abnormal 
thyroid function tests were excluded, and so were patients 
displaying active infections and pregnant women. Patients 
with clinical evidence of intravascular hemolysis (reticulocy-
tosis, abnormally high concentration of serum lactate de-
hydrogenase and indirect bilirubin, and abnormally low con-
centration of serum haptoglobin) were excluded. Standard 
single-color flow cytometry was performed for screening 
of paroxysmal nocturnal hemoglobinuria, and patients dis-
playing more than 3% of CD55- or CD59-deficient RBCs 
or granulocytes were excluded. In addition to laboratory 
investigations for determining eligibility, the serum levels 
of erythropoietin (EPO) were measured by radioimmuno-
assay at initial presentation.
2. Follow-up
  We followed eligible patients who did not undergo platelet 
transfusion or drug therapy. They were regularly monitored 
monthly for the first 3 months and then every 3 months 
for the remaining period. CBC and reticulocyte counts were 
examined at every visit. Routine chemistry, urine analysis, 
and studies to rule out systemic lupus erythematosus and 
primary antiphospholipid antibody syndrome were per-
formed once a year. When the platelet counts decreased 
further or when pancytopenia developed, BM examination 
was performed along with conventional cytogenetic studies. 
3. Statistical analyses
  Statistical analyses were performed using SPSS version 
18.0 (SPSS Inc., Chicago, IL). Correlation efficiencies among 
laboratory parameters were calculated according to Pearson’s 
principle, and P-value＜0.05 was deemed statistically signi-
ficant. 
RESULTS
1. Patient characteristics 
  Between January 2002 and December 2006, we studied 
224 patients with isolated thrombocytopenia by using techni-
ques including BM examination. Among these patients, 20 
(17 men and 3 women) were consistent with isolated throm-
bocytopenia accompanied by hypocellular marrow. The me-
dian age of the patients was 29 years (range, 18-70 years) 
(Tables 1, 2). Three young male patients aged less than 20 
years (UPN 5, 13, and 15) were referred to our hospital 
for thrombocytopenia found incidentally during routine lab-
oratory examination for military recruitment. The remainder 
of the group was referred from local clinics for further evalua-
tion of thrombocytopenia found during health examination 
or during examination for minor illness. One old male patient 
(UPN 19) had episodic easy bruising, but symptoms or signs 
commonly associated with thrombocytopenia were not ob-
served in the other patients (data not shown). Korean J Hematol 2011;46:128-34.
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Table 1. Patient characteristics and natural history.
UPN
Age 
(yr) 
Gender
Initial presentation Follow-up Follow-up 
duration 
(mo)
Status at the 
follow-up WBC 
(×10
9/L)
ANC 
(×10
9/L)
Hb 
(g/dL)
MCV 
(fL)
Platelet 
(×10
9/L)
BM
 (%)
WBC 
(×10
9/L)
ANC 
(×10
9/L)
Hb 
(g/dL)
MCV 
(fL)
Platelet 
(×10
9/L)
BM 
(%)
 1 39 M 4.57 2.51 15.0 92.5 85 25 5.88 2.97 15.4 92.9 156 − 36 (12)
a) Normalized
 2 65 M 4.28 2.49 14.7 99.2 69 10 3.21 1.52 12.0 96.7 53 10 90 (90)
a) MAA
 3 28 M 4.10 1.69 14.0 99.0 99 20 3.96 1.89 14.0 99.0 100 − 12 NC
 4 23 M 6.04 4.00 14.0 103.7 50 20 3.90 1.87 15.5 106.9 56 − 53 NC
 5 19 M 5.51 3.13 14.5 95.0 66 15 5.47 2.26 14.2 106.9 74 − 77 NC
 6 70 F 4.10 2.76 12.6 97.2 56 15 5.69 3.01 12.6 97.9 204 − 56 (56)
a) Normalized
 7 51 F 4.06 2.64 13.4 87.4 24 15 4.10 1.96 13.1 89.4 183 − 73 (66)
a) Normalized
 8 25 M 4.82 2.61 17.0 89.9 74 20 5.89 3.25 16.4 90.3 67 − 51 NC
 9 45 M 4.19 2.10 14.4 96.4 43 20 4.47 1.98 13.9 96.6 36 − 18 NC
10 25 M 4.10 2.53 15.7 107.5 67 5 4.19 2.20 14.2 106.5 43 − 22 NC
11 22 F 5.21 3.36 13.2 111.3 87 20 3.12 1.13 8.6 115.5 56 10 30 (11)
a) MAA
12 25 M 4.13 1.95 15.1 89.1 61 15 4.60 2.06 15.6 89.9 65 − 15 NC
13 18 M 5.42 1.87 16.0 105.9 54 20 4.37 2.20 15.9 95.4 69 − 50 NC
14 42 M 4.55 2.55 14.7 95.8 79 15 1.13 0.52 7.6 117.6 20 70 81 (70)
a) RCMD
15 19 M 4.79 1.89 15.6 90.5 87 15 5.05 2.04 14.7 90.9 65 − 72 NC
16 31 M 7.39 3.84 15.4 83.4 22 10 7.98 2.39 14.9 84.9 33 − 19 NC
17 63 M 5.80 2.31 14.0 111.1 56 5 4.11 2.08 15.2 106.7 63 − 38 NC
18 49 M 6.39 4.09 16.8 89.6 65 20 8.44 5.76 14.7 90.1 50 − 22 NC
19 73 M 5.93 4.39 13.4 100.6 12 5 9.08 4.11 14.7 89.5 42 − 17 NC
20 47 M 10.21 6.94 15.3 98.7 44 5 9.35 3.03 14.2 97.9 77 − 33 NC
a)Time to the events (normalization of platelet counts or development of pancytopenia).
Abbreviations: ANC, absolute neutrophil counts; MCV, mean corpuscular volume; BM, bone marrow cellularity; NC, not changed; MAA, 
moderate aplastic anemia; RCMD, refractory cytopenia with multilineage dysplasia.
Table 2. Summary of laboratory data at initial presentation (N=20).
Complete blood count
   Platelet (×10
9/L)
Median (range) 63 (12-99)
＜20 1 (5%)
20-50 3 (15%)
＞50 16 (80%)
    WBC (×10
9/L), median (range) 4.84 (4.06-12.21)
    Hemoglobin (g/dL), median (range) 14.6 (12.5-17.0)
    MCV (fL)
Median (range) 95.8 (84.4-111.3)
≤100 14 (70%)
＞100 6 (30%)
Bone marrow examination
    Cellularity (%)
Median (range) 15 (5-25)
0-10 6 (30%)
11-20 13 (65%)
21-25 1 (5%)
    Cellular distribution
Even 14 (70%)
Uneven 6 (40%)
Abbreviation: MCV, mean corpuscular volume.
  Thrombocytopenia was typically mild, with platelet counts 
ranging from 12×10
9/L to 99×10
9/L (median, 63×10
9/L). The 
platelet counts were above 50×10
9/L in 16 patients (80%) 
and between 20×10
9/L and 50×10
9/L in 3 patients (15%). 
According to the definition of isolated thrombocytopenia 
accompanied by hypocellular marrow, anemia was not pres-
ent in these patients. However, 6 of the 20 patients (30%) 
had macrocytic red blood cells (mean corpuscular volume, 
MCV＞100 fL). MCV ranged from 83.4 to 111.3 fL (median, 
95.8 fL) (Tables 1, 2). Serum EPO levels were measured 
in 15 patients. Among them, 12 patients (80%) had serum 
EPO levels higher than the upper limit of the reference 
range (3.7-31.5 mIU/mL), and 3 patients (20%) displayed 
levels greater than 3-times the upper limit. No correlation 
was observed between serum EPO levels and platelet counts 
(R
2=0.0814, P=0.264). In contrast, a weak positive correlation 
was observed between serum EPO levels and MCV (R
2= 
0.2806,  P=0.051) (Fig. 1).
  BM cellularity ranged between 5% and 25% (median, 15%) 
and was 10% or lower in 6 patients (30%), 11-20% in 13 
patients (65%), and 21-25% in 1 patient (5%). Cellular dis-
tribution was even in 14 patients (70%) and uneven in 6 
patients (30%) (Table 2, Fig. 2). There was no correlation 
between cellular distribution and platelet counts (data not 
shown). A weak positive correlation existed between BM 
cellularity and platelet counts (R
2=0.2044,  P=0.045). 
However, BM cellularity did not correlate with hemoglobin 
levels (R
2=0.0016, P=0.869) or serum EPO levels (R
2=0.0046, 
P=0.809) (Fig. 1). 
2. Clinical outcomes in long-term follow-up
  Twenty patients were followed-up for a median of 48 
months (range, 12-90 months). Platelet counts in 3 patients 
(UPN 1, 6, and 7) had recovered to normal values (＞150× 
10
9/L) during 12, 56, and 66 months of follow-up, respec-
tively. Conversely, 3 patients (UPN 2, 11, and 14) developed 
pancytopenia at 90, 11, and 70 months of follow-up, respec-Korean J Hematol 2011;46:128-34.
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Fig. 1. Relationship among laboratory parameters in patients with 
isolated thrombocytopenia accompanied by hypocellular marrow. 
Weak positive correlations were observed between serum erythro-
poietin (EPO) levels and mean corpuscular volume (MCV) (B) and 
between bone marrow (BM) cellularity and platelet counts (C). No 
correlation was observed between serum EPO levels and platelet 
counts (A), between BM cellularity and Hb levels (D), or between BM 
cellularity and serum EPO levels (E).
tively. Findings in 2 patients (UPN 2 and 11) were consistent 
with normal karyotyped moderate aplastic anemia, and 1 
patient (UPN 14) was confirmed as having normal kar-
yotyped refractory cytopenia with multilineage dysplasia 
(RCMD). No severe aplastic anemia, leukemia, paroxysmal 
nocturnal hemoglobinuria, or autoimmune disorders were 
observed. The platelet counts remained unchanged in the 
remainder of patients during the follow-up for a median 
of 27.5 months (range, 12-77 months) (Tables 1, 3). One 
patient with aplastic anemia (UPN 11) was placed on im-
munosuppressive therapy consisting of antithymocyte glob-
ulin and cyclosporine, which resulted in complete response. 
The RCMD patient underwent allogeneic hematopoietic 
stem cell transplantation and has been healthy with normal 
CBC for 3 months after transplantation.Korean J Hematol 2011;46:128-34.
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Fig. 2. Representative bone mar-
row biopsy findings (hematoxylin 
and eosin [H&E] stain, ×100). (A)
Marked hypocellularity with even 
cellular distribution (from UPN 1). 
(B)  Marked hypocellularity with 
focally uneven cellular distribution
(UPN 15). (C) Moderate hypocel-
lularity with even cellular distribu-
tion (from UPN 14).
Table 3. Natural history of patients
a) (N=20).
Status
No. of 
patients (%)
Follow-up duration, 
median (range)/
Time to events (mo)
Remained unchanged 14 (70) 27.5 (12-77)
Complete recovery of    3 (15) 12, 56, 66
 platelet counts
Progression to pancytopenia   3 (15)
    Moderate aplastic anemia   2 11, 90
    RCMD   1 70
a)Patients were followed up for a median of 48 months (range, 
12-90 months).
Abbreviation: RCMD, refractory cytopenia with multilineage dys-
plasia.
DISCUSSION
  Recently, a significant increase has been observed in in-
cidentally discovered thrombocytopenia, most likely because 
extensive and regular health examinations are being con-
ducted. Mild to moderate thrombocytopenia is also identified 
during routine laboratory examination given to young adults 
during military recruitment. If the relevant causes for throm-
bocytopenia are not determined in these patients, ITP is 
the most suitable diagnosis. However, thrombocytopenia is 
difficult to diagnose, if the BM examination reveals a mark-
edly decreased cellularity without significant dysplasia, sug-
gesting myelodysplastic syndrome (MDS), or megakaryocytic 
hyperplasia, suggesting ITP. In some cases, the relative in-
crease in the number of megakaryocytes, despite decreased 
cellularity, is evident. This suggests ITP and a likely response 
to corticosteroid treatment. In many cases, however, it is 
difficult to determine the presence of dyshematopoiesis or 
megakaryocytic hyperplasia because of the paucity of the 
cells in BM aspirates and marked hypocellularity in BM 
biopsies.
  A decrease in BM cellularity is observed in several hemato-
logic disorders, including aplastic anemia, hypoplastic MDS, 
and hypoplastic leukemia, and distinguishing one from an-
other is not always easy [11-13]. In the present study, only 
patients having definite hypocellular marrow, without evi-
dence of megakaryocytic hyperplasia, were included, thereby 
precluding the possibility that some of the patients might 
have ITP, because marrow hypocellularity is not a compo-
nent of ITP. Although screening for Helicobacter pylori (H. 
pylori) infection is currently recommended in the work-up 
of adults with typical ITP [9], we did not perform H. pylori 
test in the present study because the benefits of testing were 
unproven or controversial during the period of patient enroll-
ment. In future studies, sensitive H. pylori testing will be 
required.
  A prerequisite for aplastic anemia is pancytopenia or bicy-
topenia, in addition to hypoplastic or aplastic marrow. The 
patients included in this study did not meet the criteria 
for aplastic anemia. Patients showing significant dyshemato-
poiesis or abnormal localization of immature precursors in 
BM examination were also excluded from the present study, 
even though dysplasia was difficult to assess in some instances 
due to the paucity of cells in the aspirates. Immunostain 
for CD34, CD117, or myeloperoxidase on BM biopsy speci-
mens has recently been reported to be helpful in distinguish-
ing hypocellular MDS from aplastic anemia [13-15]. In addi-
tion, high-resolution whole-genome tiling path array com-
parative genomic hybridization analysis of CD34+ cells from 
patients with MDS having normal karyotypes can reveal 
cryptic copy number alterations [16]. However, it remains 
unknown whether these additional laboratory studies are 
helpful in further defining isolated thrombocytopenia ac-
companied by hypocellular marrow. Although we did not Korean J Hematol 2011;46:128-34.
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perform immunostain or molecular examination, the patients 
in the present study did not meet the criteria for MDS as 
proposed by the WHO [17]. Because it is sometimes difficult 
to diagnose low-risk MDS in patients with mild cytopenia, 
a provisional diagnosis of idiopathic cytopenia of undeter-
mined significance (ICUS) has been proposed. ICUS was 
diagnosed in 10 patients with mild to marked unexplained 
cytopenia without definite signs of a myeloid neoplasm [18]. 
Since all patients displayed normocellular marrow, the pa-
tients in our study could not be classified as having ICUS. 
Some of the patients showed an uneven cellular distribution 
in the BM study. The clinical implications of this finding, 
however, remain unknown, and further studies are required. 
  In the present study, 2 of 20 patients showed pancytopenia 
consistent with aplastic anemia during follow-up, indicating 
a subgroup, in which isolated thrombocytopenia accom-
panied by hypocellular marrow can be a prodrome of aplastic 
anemia. These patients tended to display higher levels of 
serum EPO and larger MCV at initial presentation, suggesting 
that anemia was not apparent, because erythropoiesis had 
already been stimulated through a compensatory mechanism. 
This notion is further supported by a positive correlation 
between serum EPO levels and MCV. Therefore, a closer 
follow-up is required in patients who display higher serum 
EPO levels and larger MCV. One of the 20 patients displayed 
MDS 7 years later, indicating that isolated thrombocytopenia 
accompanied by hypocellularity can present as an early mani-
festation of MDS. Conversely, the platelet counts were nor-
malized during follow-up in 3 patients, suggesting that iso-
lated thrombocytopenia accompanied by hypocellularity is 
a heterogeneous condition and that a subgroup of this dis-
order represents a temporary BM depression of unknown 
cause. These observations suggest that longer follow-up is 
required even in patients who do not show any changes 
in CBC during short-term follow-up. If the patients in the 
present study had not undergone BM examination, they 
would have been classified as having ITP. Thus, BM examina-
tion may be necessary even in isolated thrombocytopenia, 
at least in the Korean subjects. Taken together, these findings 
lead us to propose a provisional diagnosis of isolated thrombo-
cytopenia accompanied by hypocellular marrow for patients 
who display platelet counts below 100×10
9/L and hypocel-
lularity that is not associated with megakaryocytic hyper-
plasia or significant dysplasia on BM examination.
  In conclusion, isolated thrombocytopenia accompanied by 
hypocellular marrow encompasses a group of heterogeneous 
conditions, and its subgroups represent the early manifes-
tations of aplastic anemia, MDS, or temporary BM depression 
of unknown cause. Regular follow-up is therefore mandatory 
in patients with this condition, and a large-scale observa-
tional study is warranted. In forthcoming studies, vigilant 
laboratory investigations, including immunostaining for 
CD34, CD117, or myeloperoxidase of BM biopsy specimens 
and molecular studies using BM CD34+ cells, may be re-
quired.
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